MedPath
HSA Approval

AMOXAPEN 250 FOR ORAL SUSPENSION 250 mg/5 ml

SIN00472P

AMOXAPEN 250 FOR ORAL SUSPENSION 250 mg/5 ml

AMOXAPEN 250 FOR ORAL SUSPENSION 250 mg/5 ml

April 22, 1988

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

POWDER, FOR SUSPENSION

ORAL

Medical Information

J01CA04

amoxicillin

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

REMEDICA LTD

Active Ingredients

AMOXYCILLIN TRIHYDRATE EQV AMOXYCILLIN

250MG/5ML

Amoxicillin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

AMOXAPEN 250 FOR ORAL SUSPENSION 250 mg/5 ml - HSA Approval | MedPath